Telix Pharmaceuticals: Funding, Investors & Team (Sep 2026)
Telix Pharmaceuticals Ltd is a clinical-stage biotechnology company engaged in developing and commercializing molecularly-targeted radiation therapy to address the unmet needs in the management of prostate, renal (kidney) and glioblastoma (brain) cancer.
Telix Pharmaceuticals has raised $1.1B across 3 funding rounds on record, the most recent an undisclosed round of $600M announced in Apr 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Telix Pharmaceuticals Company Profile and Key Stats
Latest funding round on record: Apr 2026.
Telix Pharmaceuticals Funding Rounds
Telix Pharmaceuticals raised $23.0M in a Grant announced in Apr 2022.
2.3 years later, an undisclosed round of $431M was announced in Jul 2024.
1.8 years later, an undisclosed round of $600M was announced in Apr 2026.
Telix Pharmaceuticals Founders and Leadership Team
Contact details for the Telix Pharmaceuticals team: 1 of 2 have an email address on file.
Start 14-day free trial →Telix Pharmaceuticals Funding Compared to Other Biotechnology Startups
Telix Pharmaceuticals' latest round of $600M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Telix Pharmaceuticals in Biotechnology and Melbourne
Companies Similar to Telix Pharmaceuticals
AdvanCell is a company that focuses on developing innovative cancer treatments using alpha-emitting isotopes…
The objective of Fluent is to seamlessly integrate humans with AI, improving interaction and communication…
Mesoblast is a developer of biologic products for the broad field of regenerative medicine. Mesoblast's…
Microba Life Sciences Ltd. provides consumers, doctors, and researchers with gut microbiome testing services…
Algenie was founded on a simple realization: algae has the potential to save the earth, but only if it is…
Paradigm Pharmaceuticals is a global biopharmaceutical company driven to discover, develop, and deliver…
Imugene is a publicly-listed biotechnology company with operations in America and Europe,
BiomeBank’s mission is to treat and prevent disease by restoring gut microbial ecology
Cauldron Ferm is a technique that speeds up the production of precision fermented prototypes to commercial…
HydGene Renewables is developing a biotechnology platform that produces on-site green hydrogen from waste…
Swan Genomics is focused on commercialising an innovative new approach to DNA sequencing to deliver more…
OncoRes Medical develops an imaging technology to provide intraoperative information available to surgeons to…
Telix Pharmaceuticals Funding FAQs
What does Telix Pharmaceuticals do?
Telix Pharmaceuticals Ltd is a clinical-stage biotechnology company engaged in developing and commercializing molecularly-targeted radiation therapy to address the unmet needs in the management of prostate, renal (kidney) and glioblastoma (brain) cancer.
How much funding has Telix Pharmaceuticals raised?
Telix Pharmaceuticals has raised $1.1B across 3 rounds on record. The most recent is an undisclosed round of $600M announced in Apr 2026.
When did Telix Pharmaceuticals last raise funding?
Telix Pharmaceuticals' most recent funding round on record is an undisclosed round of $600M, announced in Apr 2026.
Who founded Telix Pharmaceuticals?
FundedIQ lists Chris Behrenbruch (Founder), Christian Behrenbruch (Founder) at Telix Pharmaceuticals.
Where is Telix Pharmaceuticals headquartered?
Telix Pharmaceuticals is based in Melbourne, Victoria, Australia.
How many employees does Telix Pharmaceuticals have?
Telix Pharmaceuticals is in the 101-250 employee band.
How does Telix Pharmaceuticals' funding compare to other Biotechnology startups?
Telix Pharmaceuticals' latest round of $600M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Telix Pharmaceuticals Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Telix Pharmaceuticals is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.